EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Concomitant Metamizole Treatment on the Exposure of Mould‐Active Triazoles

Dorian Vanneste iD, Ine De Booser, Kristina Nadrah, Matej Somrak, Matthias Gijsen, Aleš Matos, Katja Kalan, Bart Morlion, Steffen Rex, Saba Battelino, Katrien Lagrou, Johan Maertens und 1 weitere

Mycoses · 2026-05 · 69 (5)

DOI: 10.1111/myc.70173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mycoses, online erschienen am 14.05.2026. Verfasst von Dorian Vanneste und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Dipyrone, Triazoles, Antifungal Agents, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Metamizole is an analgesic drug with moderate cytochrome P450 (CYP) inductive properties. The antifungal triazoles are metabolized by several CYP enzymes, but the interaction with metamizole remains poorly described. We investigated the influence of metamizole on the exposure of voriconazole, isavuconazole, and posaconazole.

Methods

Patients from UZ Leuven (Belgium) and Ljubljana University Medical Centre (Slovenia) receiving voriconazole, isavuconazole, or posaconazole concomitantly with metamizole were included in the study. Routine therapeutic drug monitoring (TDM) measurements collected between January 2019 and December 2024 were retrieved retrospectively. TDM concentrations outside of concomitant therapy were collected as controls. The influence of metamizole and other clinically relevant covariates was analysed using generalized estimating equations (GEE).

Results

A total of 126 distinct treatments with a triazole from 115 patients, accounting for 392 measurements, were included in the study. GEE analysis revealed a significant negative association between the 7‐day cumulative metamizole dose and lower voriconazole and posaconazole concentrations. Additionally, C‐reactive protein had a positive association with voriconazole concentrations. Only ICU admission and patient characteristics, that is, sex and weight, had a significant influence on isavuconazole concentrations.

Conclusion

Concomitant therapy with metamizole led to lower voriconazole and posaconazole concentrations, presumably through induction of CYP enzymes and possibly UDP‐glucuronyltransferase. We recommend avoiding concomitant use of metamizole with the antifungal triazoles to prevent underexposure and treatment failure or frequent TDM if the combination cannot be avoided. Further studies are needed to confirm our findings and investigate the influence of metamizole on other triazoles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DipyroneTriazolesAntifungal AgentsAnti-Inflammatory Agents, Non-SteroidalHumansDrug InteractionsVoriconazoleRetrospective StudiesFemaleMaleDrug MonitoringMiddle AgedAgedNitrilesPyridines

Stichwörter der Autor:innen

drug interactionsmetamizolemould‐active triazoles

Substanzen

DipyroneTriazolesAntifungal AgentsVoriconazoleisavuconazoleposaconazoleAnti-Inflammatory Agents, Non-SteroidalNitrilesPyridines

Autor:innen und Institutionen

  • Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
  • Department of Infectious Diseases, University Medical Center, Ljubljana, Slovenia.
  • Institute of Clinical Chemistry and Biochemistry, University Medical Center Ljubljana, Slovenia.
  • Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.
  • Grošelj Matos Otorinolaringologija, Ljubljana, Slovenia.
  • Pharmacy Department, University Medical Centre, Ljubljana, Slovenia.

ORCID-Profile: Dorian Vanneste

Zitieren

APA

Vanneste, D., De Booser, I., Nadrah, K., Somrak, M., Gijsen, M., Matos, A., Kalan, K., Morlion, B., Rex, S., Battelino, S., Lagrou, K., Maertens, J., & Spriet, I. (2026). Impact of Concomitant Metamizole Treatment on the Exposure of Mould‐Active Triazoles. Mycoses, 69(5). https://doi.org/10.1111/myc.70173

Vancouver

Vanneste D, De Booser I, Nadrah K, Somrak M, Gijsen M, Matos A, et al. Impact of Concomitant Metamizole Treatment on the Exposure of Mould‐Active Triazoles. Mycoses. 2026;69(5). doi:10.1111/myc.70173

BibTeX
@article{Vanneste2026,
  author = {Vanneste, Dorian and De Booser, Ine and Nadrah, Kristina and Somrak, Matej and Gijsen, Matthias and Matos, Aleš and Kalan, Katja and Morlion, Bart and Rex, Steffen and Battelino, Saba and Lagrou, Katrien and Maertens, Johan and Spriet, Isabel},
  title = {Impact of Concomitant Metamizole Treatment on the Exposure of Mould‐Active Triazoles},
  journal = {Mycoses},
  year = {2026},
  volume = {69},
  number = {5},
  doi = {10.1111/myc.70173}
}
Kostenlos starten →